Dosing

TREMFYA^® DOSING IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
A SINGLE, 100 MG DOSE ONCE EVERY 8 WEEKS AFTER ONLY 2 STARTER DOSES¹

FREQUENCY OF INJECTIONS FOR SUBCUTANEOUS (SC) BIOLOGICS (FIRST 52 WEEKS) IN ADULTS

*Based on the recommended 300 mg dose. 150 mg may be acceptable for some patients.

^†In addition to the 50 mg, twice-weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. The proportion of responders was related to Enbrel® dosage.

This presentation is not intended to compare the relative safety or efficacy of these treatments. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product's Prescribing Information for additional information.

STELARA® is indicated for the treatment of patients 12 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up visits with a physician. In adolescent patients, it is recommended that STELARA® be administered by a healthcare provider. If a physician determines that is is appropriate, a patient may self-inject or a caregiver may inject STELARA® after proper training in subcutaneous injection technique. Patients should be instructed to follow the directions provided in the Medication Guide. View the Important Safety Information for STELARA®.
Taltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Humira® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Siliq™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Cosentyx® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
Indicated trademarks are registered trademarks of their respective owners.

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

References: 1. TREMFYA® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 2. STELARA® (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 3. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 4. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 5. Siliq™ (brodalumab) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC. 6. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 7. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA^®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v1